PODGORICA, MONTENEGROvia eTeligis -- Neuro -Biotech Corp. (OTC Pink: MRES) announced today that it completed the acquisition of the Institute of Biomedical Research (the "Institute"), which is now a wholly-owned subsidiary of MRES. The Company's official website is now: www.institutebmr.com .
The Institute of Biomedical Research is an ambitious biomedical business venture whose activities extend from highly diversified scientific research and sophisticated services research and development, quality control and standardisation of pharmaceuticals, (cosmetics and food products) up to major long term biomedical and environmental research projects, as well as the development of new diagnostic technologies and innovative experimental medical treatments. Regulatory certification of new drugs and biomedical products also constitutes important business activities of the Institute. The Institute is essential for the development of Montenegro within the regional and European environment.
Dr. Drasko Pekovic , the new President of MRES, said, "This transaction is a large step forward in the development of the Institute, and we envision that it will be instrumental in our forward progress."
The transaction was achieved by the acquisition by MRES of all of the stock of the Institute in exchange for newly issued stock of MRES. The shareholders of the Institute, Dr. Drasko Pekovic and the Government of Montenegro, now hold majority control of MRES.
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although Neuro -Biotech Corp. (the "Company" or "MRES") believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Ceres Ventures will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's filings with OTCMarkets.com. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CONTACT:
Institute of Biomedical Research
Ljubljanska bb
81000 Podgorica,
Montenegro
Dr. Drasko Pekovic CEO
Email: info@InstituteBMR.com
SOURCE: Neuro -Biotech Corp.
